Page 1 | Search Results | Blood | American Society of Hematology

1-11 of 11

Sort by

Sort Order Select

Journal Articles

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Gerhard Zugmaier, Nicola Gökbuget, Matthias Klinger, Andreas Viardot, Matthias Stelljes, Svenja Neumann, Heinz-A. Horst, Reinhard Marks, Christoph Faul, Helmut Diedrich, Albrecht Reichle, Monika Brüggemann, Chris Holland, Margit Schmidt, Hermann Einsele, Ralf C. Bargou, Max S. Topp

Blood (2015) 126 (24): 2578–2584.

https://doi.org/10.1182/blood-2015-06-649111

Published: 2015

Includes: Supplemental data

Journal Articles

Long-Term Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Achieved Minimal Residual Disease (MRD) Response Following Anti-CD19 BiTE ® Blinatumomab

Gerhard Zugmaier, Nicola Goekbuget, Andreas Viardot, Matthias Stelljes, Svenja Neumann, Heinz A. Horst, Albrecht Reichle, Reinhard Marks, Christoph Faul, Monika Brueggemann, Chris Holland, Margit Schmidt, Noemi Mergen, Marie-Elisabeth Goebeler, Hermann Einsele, Ralf C. Bargou, Max S. Topp

Blood (2014) 124 (21): 2287.

https://doi.org/10.1182/blood.V124.21.2287.2287

Published: 2014

Journal Articles

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Blood (2012) 120 (26): 5185–5187.

https://doi.org/10.1182/blood-2012-07-441030

Published: 2012

Journal Articles

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

Blood (2011) 118 (21): 1637.

https://doi.org/10.1182/blood.V118.21.1637.1637

Published: 2011

Journal Articles

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Blood (2010) 116 (21): 174.

https://doi.org/10.1182/blood.V116.21.174.174

Published: 2010

Journal Articles

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m 2 /d Is Tolerable and Highly Effective

Andreas Viardot, MD, Mariele Goebeler, MD, Jurgen S. Scheele, MD, PhD, Gerhard Zugmaier, MD, Richard Noppeney, MD, Stefan Knop, MD, Max S Topp, MD, Dirk Nagorsen, MD, Matthias Klinger, PhD, Margit Schmidt, PhD, Petra Klappers, Peter Kufer, MD, Hermann Einsele, MD, Ralf Bargou, MD

Blood (2010) 116 (21): 2880.

https://doi.org/10.1182/blood.V116.21.2880.2880

Published: 2010

Journal Articles

Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m 2 /d of BiTE® Antibody Blinatumomab.

Dirk Nagorsen, Gerhard Zugmaier, Andreas Viardot, Mariele Goebeler, Richard Noppeney, Margit Schmidt, Petra Klappers, Patrick A Baeuerle, Peter Kufer, Ralf C Bargou

Blood (2009) 114 (22): 2723.

https://doi.org/10.1182/blood.V114.22.2723.2723

Published: 2009

Journal Articles

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Blood (2009) 114 (22): 840.

https://doi.org/10.1182/blood.V114.22.840.840

Published: 2009

Journal Articles

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Dirk Nagorsen, Gerhard Zugmaier, Peter Kufer, Matthias Klinger, Andreas Viardot, Mariele Goebeler, Margit Schmidt, Petra Klappers, Andreas Wolf, Christian Brandl, Patrick A Baeuerle, Ralf C Bargou

Blood (2009) 114 (22): 4798.

https://doi.org/10.1182/blood.V114.22.4798.4798

Published: 2009

Journal Articles

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

Max Topp, MD, Nikola Goekbuget, MD, Peter Kufer, MD, Gerhard Zugmaier, MD, Evelyn Degenhard, Svenja Neumann, MD, Heinz A Horst, MD, Andreas Viardot, MD, Mathias Schmid, MD, Oliver G. Ottmann, MD, Margit Schmidt, PhD, Carsten Reinhardt, MD, Patrick A Baeuerle, PhD, Dirk Nagorsen, MD, Dieter Hoelzer, MD, PhD, Ralf C. Bargou, MD

Blood (2008) 112 (11): 1926.

https://doi.org/10.1182/blood.V112.11.1926.1926

Published: 2008

Journal Articles

Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL

Ralf C Bargou, MD, Peter Kufer, MD, Mariele Goebeler, MD, Stefan Knop, MD, Hermann Einsele, MD, Richard Noppeney, MD, Andreas Viardot, MD, Patrick A Baeuerle, PhD, Carsten Reinhardt, MD, Margit Schmidt, PhD, Petra Klappers, Dirk Nagorsen, MD, Gerhard Zugmaier, MD

Blood (2008) 112 (11): 267.

https://doi.org/10.1182/blood.V112.11.267.267

Published: 2008

NARROW

Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment

Long-Term Survival in Adult Patients with Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) Who Achieved Minimal Residual Disease (MRD) Response Following Anti-CD19 BiTE ® Blinatumomab

Long-term follow-up of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage ALL

Blinatumomab Monotherapy Shows Efficacy in Patients with Relapsed Diffuse Large B Cell Lymphoma

CD19/CD3 Bispecific Antibody Blinatumomab (MT-103) Is Highly Effective In Treatment of Patients with Minimal Residual Disease From Chemotherapy-Resistant B-Precursor Acute Lymphoblastic Leukemia

Treatment of Patients with Non-Hodgkin Lymphoma (NHL) with CD19/CD3 Bispecific Antibody Blinatumomab (MT103): Double-Step Dose Increase to Continuous Infusion of 60 μg/m 2 /d Is Tolerable and Highly Effective

Confirmation of Safety, Efficacy and Response Duration in Non-Hodgkin Lymphoma Patients Treated with 60 μg/m 2 /d of BiTE® Antibody Blinatumomab.

Report of a Phase II Trial of Single-Agent BiTE® Antibody Blinatumomab in Patients with Minimal Residual Disease (MRD) Positive B-Precursor Acute Lymphoblastic Leukemia (ALL).

Transient Laboratory Findings Upon First Dosing with T-Cell Engaging BiTE® Antibody Blinatumomab in Non-Hodgkin Lymphoma Patients.

Treatment with Anti-CD19 BiTE Antibody Blinatumomab (MT103 / MEDI-538) Is Able to Eliminate Minimal Residual Disease (MRD) in Patients with B-Precursor Acute Lymphoblastic Leukemia (ALL): First Results of An Ongoing Phase II Study.

Sustained Response Duration Seen after Treatment with Single Agent Blinatumomab (MT103/MEDI-538) in the Ongoing Phase I Study MT103- 104 in Patients with Relapsed NHL

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only